That's an important distinction
Back in June, Novo abruptly ended a monthlong collaboration with Hims & Hers to make its weight loss drug Wegovy available on the telehealth company's platform
Pricing is very competitive
Well notify you once we receive an outcome
The article says the decision involves more than age or weight: providers typically evaluate BMI status, obesity-related complications, documented metabolic dysfunction, cardiovascular risk, previous weight-loss interventions, and family history of metabolic disease
These timelines are subject to change based on scientific, regulatory, and market factors, as well as the capability to manufacture and distribute the drug at scale